--- Here are some potential actions covered in the article for payers and employers to take as a result of this shift: Update formulary tiers and step therapy policies (consider the impact on comorbidities) Support members transitioning off GLP-1s after reaching their goals Create differentiated access pathways based on patient risk profiles Monitor realworld outcomes beyond A1C (cardiovascular, renal, adherence) Model the downstream impact on generics and legacy therapies --- Commercial plans are accelerating GLP-1 uptake and favoring the simplicity of a single therapy
Clinical trials have shown that some carnitine forms, such as ALCAR, reduce pain and vascular-related symptoms in diabetic patients as well
Glucagon-like peptide-1 (GLP-1) is a naturally occurring incretin hormone primarily produced by L-cells in the small intestine, playing a major role in regulating blood sugar levels, appetite, and overall metabolic health
Strategic Scheduling: If possible, schedule your fasting blood test for early in the morning
Four weeks
Many pharmacies default to this strength because it allows for relatively low unit measurements across the full titration schedule
